The American Society of Clinical Oncology (ASCO) has amended its 2023 guidelines on systemic therapy for small cell lung cancer (SCLC). The same expert panel that developed the original guideline has made this amendment based on the latest clinical evidence. This article outlines the key recommendations from the guidelines. Key recommendations Treat patients with limited-stage-SCLC (LS-SCLC) who have completed concurrent chemoradiotherapy and have no disease progression with consolidation immunotherapy (durvalumab) for up to two years.
Ensure that there are no contraindications to immunotherapy. Consolidation immunotherapy (durvalumab) may be offered to patients with LS-SCLC and Eastern Cooperative Oncology Group Performance Status (ECOG PS) 3-4 due to SCLC for up to two years, provided there is improvement in PS and no contraindications to immunotherapy. Single-agent systemic therapy…
